Clinical Trial Update: Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ipatasertib with docetaxel in metastatic non-small cell lung cancer after failure of first-line immunotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Jun Zhang, MD, PhD | Conditions: NSCLC Stage IV, NSCLC Stage IIIB | Phase 2 | Status: UNKNOWN